Shares of Surgery Partners Inc (NASDAQ:SGRY) have been given an average rating of “Buy” by the seven ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $16.30.
SGRY has been the topic of several recent research reports. Benchmark lifted their price target on Surgery Partners from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Zacks Investment Research raised Surgery Partners from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research report on Thursday. UBS Group cut their target price on Surgery Partners from $19.00 to $17.50 and set a “neutral” rating on the stock in a research note on Monday, July 27th. Royal Bank of Canada reaffirmed a “buy” rating and set a $14.00 price target on shares of Surgery Partners in a research note on Wednesday, May 13th. Finally, Citigroup boosted their price objective on shares of Surgery Partners from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th.
Shares of SGRY stock opened at $15.27 on Tuesday. The company has a debt-to-equity ratio of 2.84, a quick ratio of 1.37 and a current ratio of 1.49. Surgery Partners has a 52 week low of $4.00 and a 52 week high of $19.74. The company’s 50 day moving average price is $12.74 and its two-hundred day moving average price is $12.62.
Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.28. The company had revenue of $441.00 million during the quarter, compared to the consensus estimate of $377.50 million. Surgery Partners had a negative net margin of 4.38% and a negative return on equity of 2.21%. On average, analysts predict that Surgery Partners will post -1.16 earnings per share for the current year.
A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its position in shares of Surgery Partners by 0.9% during the 4th quarter. Bank of New York Mellon Corp now owns 96,818 shares of the company’s stock worth $1,516,000 after purchasing an additional 884 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in Surgery Partners by 1.8% during the first quarter. BNP Paribas Arbitrage SA now owns 107,675 shares of the company’s stock worth $703,000 after buying an additional 1,859 shares during the last quarter. Kennedy Capital Management Inc. raised its position in Surgery Partners by 1.1% during the fourth quarter. Kennedy Capital Management Inc. now owns 350,309 shares of the company’s stock worth $5,484,000 after acquiring an additional 3,686 shares in the last quarter. Rhumbline Advisers lifted its stake in Surgery Partners by 11.6% in the first quarter. Rhumbline Advisers now owns 38,829 shares of the company’s stock valued at $254,000 after acquiring an additional 4,025 shares during the last quarter. Finally, Dimension Capital Management LLC grew its position in shares of Surgery Partners by 3.4% in the 1st quarter. Dimension Capital Management LLC now owns 190,870 shares of the company’s stock valued at $1,246,000 after acquiring an additional 6,356 shares during the period. Hedge funds and other institutional investors own 93.04% of the company’s stock.
About Surgery Partners
Surgery Partners, Inc, through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.
Featured Story: Why is the LIBOR significant?
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.